ClinicalTrials.gg
CompletedNCT04395911Updated Aug 5, 2021

Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections

An interventional study of SCD in AKI, ARDS and COVID, sponsored by SeaStar Medical. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-08-05.

Sponsored by SeaStar Medical · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2021, 5 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Selective Cytopheretic Device (SCD) treatments will improve survival in patients testing positive for COVID-19 infection diagnosed with Acute Kidney Injury (AKI) or ARDS.

02

Conditions studied

  • AKI
  • ARDS
  • COVID
03

In context

Lead sponsor

SeaStar Medical is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained
  • Positive COVID-19 test
  • Must be receiving medical care in an intensive care nursing situation
  • Non-pregnant females
  • Intent to deliver full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours.
  • count >30,000/mm3 at Screening
  • Clinical diagnosis of AKI requiring CRRT or ARDS

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular instability that precludes initiation of continuous renal replacement therapy (CRRT).
  • Irreversible brain damage based on available historical and clinical information.
  • Presence of any solid organ transplant at any time.
  • Patients with stem cell transplant in the previous 100 days or who have not engrafted.
  • Acute or chronic use of circulatory support device other than ECMO such as LVADs, RVADs, BIVADs.
  • which is actively being treated or may be treated with chemotherapy or radiation during the subsequent three month period after study treatment.
  • Chronic defined as >20 mg prednisone qd alone without other immunosuppressant medications (ie (cyclophosphamide, azathioprine, methotrexate, rituximab, mycophenolate, cyclosporine).
  • Patient is moribund or chronically debilitated for whom full supportive care is not indicated.
  • Concurrent enrollment in another interventional clinical trial. Patients enrolled in observational studies (NO TEST DEVICE OR DRUG USED) are allowed to participate.
  • Any reason the Investigator deems exclusionary.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Other
    SCD

    Cytopheretic device

    Device: SCD

Interventions

  • DeviceSCD

    cytopheretic device

06

What researchers measure

Primary outcomes

  1. Mortality at Day 60

    All cause mortality at Day 60

    Time frame: 60 days post treatment

  2. Dialysis Dependency

    Dialysis Dependency at Day 60

    Time frame: 60 days post treatment

  3. Ventilation at Day 28

    Ventilation free survival at Day 28

    Time frame: 28 days post treatment

Secondary outcomes

  1. Dialysis Dependency

    Dialysis Dependency at Day 28

    Time frame: 28 days post treatment

  2. Mortality at Day 28

    All cause mortality at Day 28

    Time frame: 28 days post treatment

  3. Urinary output change

    Change from baseline in urine output

    Time frame: 10 days of treatment

  4. P02/FiO2 change

    Change from baseline in PO2/FiO2

    Time frame: 10 days of treatment

  5. Safety Assessments

    Assessment of SAEs, AE and UADEs

    Time frame: 10 days of treatment

  6. SCD Integrity

    Assessment of device performance

    Time frame: 10 days of treatment

07

Study locations

3 sites
  • University of Kentucky
    Lexington, Kentucky 40506, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
08

References and documents

Individual participant data

Plan to share: Yes — Unidentified participant data collected for this study will be submitted to a CRO for data analysis. All data will be submitted to the Sponsor.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be collected throughout the study conduct.

Access criteria: Participant data will be accessible to the Investigational Site and CRO through a secured electronic data capture system. CRO personnel will be responsible for data verification. De-identified Participant information will be accessible to the CRO and the Sponsor.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jul 2021, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2020
First posted
May 20, 2020
StartActual
Sep 10, 2020
Primary completionActual
Jul 5, 2021
CompletionActual
Jul 21, 2021
Last update
Aug 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04395911
Lead sponsor
SeaStar Medical
Responsible party
Sponsor
First posted
May 20, 2020
Start date
Sep 10, 2020
Primary completion
Jul 5, 2021
Completion
Jul 21, 2021
Last update
Aug 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion